<!doctype html>
<html>
  <head>
    <title> Therapy for Alzheimer</title>
    <meta charset="utf-8">
    <link rel="shortcut icon" href="https://static.wixstatic.com/media/610b77_a20e48a923544857b4f09799e844163d%7Emv2.png/v1/fill/w_32%2Ch_32%2Clg_1%2Cusm_0.66_1.00_0.01/610b77_a20e48a923544857b4f09799e844163d%7Emv2.png" type="image/png"/>
    <link rel="apple-touch-icon" href="https://static.wixstatic.com/media/610b77_a20e48a923544857b4f09799e844163d%7Emv2.png/v1/fill/w_32%2Ch_32%2Clg_1%2Cusm_0.66_1.00_0.01/610b77_a20e48a923544857b4f09799e844163d%7Emv2.png" type="image/png"/>
  </head>
  <body>
    <h1><center><a href="index.html">Clearance of Amyloid Beta and Tau in Alzheimer’s Disease:<br> from Mechanisms to Therapy</a></center></h1>
    <ol>
      <li><a href="a.html">Abstract</a></li>
      <li><a href="b.html">Introduction</a></li>
      <li><a href="c.html">The Protein Clearance machinery</a></li>
    </ol>
    <h2> Summary & at glance </h2>
    <h3> The Protein Clearance Machinery </h3>
      <p style="margin-top:15px;">Therapy targeting Aβ and tau clearance. Targeting Aβ clearance: 1, 25(OH) 2D3 and oleocanthal can increase BBB clearance of Aβ by enhancing levels of LRP1 expressed in <a href="https://en.wikipedia.org/wiki/Blood%E2%80%93brain_barrier" target="_blank" title="Blood-brain barrier">BBB</a>. Late exercise also increases Aβ clearance via the BBB, but the specific mechanism is not known. </p><br>
      <center><img src="summary.png" width="70%"></center>
      <br><p style="margin-top:15px;"> Donepezil, rivastigmine, and 1, 25(OH) 2D3 improve Aβ clearance in the liver via the increased expression of LRP1. Withania somnifera also promotes clearance in liver by increasing lipoprotein receptor-related protein levels. Cilostazol increases vascular activities to improve perivascular drainage of Aβ. Dietary pre-administration of docosahexaenoic acid can enhance RBCs antioxidant status to promote Aβ clearance. Rosiglitazone and pioglitazone increase the expression of CD36 in microglia and enhance Aβ phagocytosis. Exercise training increases levels of NEP, IDE, and MMP9. Statin, EPA, DHA, and somatotatin increase IDE levels. Simvastatin, atorvastatin, and nobiletin increase NEP levels. They all improve levels of proteases to decrease Aβ. Tenuigenin acts on the 26S proteasome to improve Aβ degradation by UPS. Methylene blue, lithium, and trehalose can join in the formation of ALS to induce Aβ by ALS. Wogonin, rapamycin, temsirolimus, and protein phosphatase 2A agonists reduce Aβ by enhancing ALS in an mTOR-dependent way. Targeting tau clearance: aerobic exercise decreases tau levels by promoting ALS activity in an mTOR-dependent way. Proteasome inhibitors and trehalose improve Co-chaperone BAG3 levels to induce tau clearance by ALS. </p>
      <p style="margin-top:15px;">Electroacupuncture and small- molecule enhancer of rapamycin-28 can induce ALS to degrade tau. Epigallocatechin-3-gallate increases the mRNA expression of autophagy adaptor NDP52 and P62 to induce tau clearance. Anti-tau monoclonal antibody MC1 can promote tau clearance by microglial phagocytosis. Ginsenoside Rg1 granulocyte-colony stimulating factor increases NEP and cyclen-hybrid artificial ‘hydrolase’ MMP9I1-Cu (II) enhances levels of proteases, both of which degrade tau levels. Rolipram decreases tau levels via improving the activity of UPS through acting on the 26S proteasome.</p>
  </body>
</html>
